Halt Medical, Inc. Announces The Commercial Release Of Acessa Guidance System

May 16, 2016


New technology to expand capabilities of laparoscopic radiofrequency ablation for the treatment of uterine fibroids

Brentwood, CA. (May 16, 2016) — Halt Medical, Inc. announced today the commercial release of the Acessa® Guidance System¹. Acessa Guidance System incorporates electromagnetic tracking technology and radiofrequency ablation to treat symptomatic uterine fibroids laparoscopically. When coupled with ultrasound, it provides instant feedback of device trajectory to the targeted fibroid and tracks the surgical instruments in real time. This is the first time in history that this technology has been applied in the field of gynecology.

“The Acessa Guidance System takes laparoscopic radiofrequency ablation of fibroids to a new level,” said Kim Bridges, President and CEO, Halt Medical, Inc. “With the launch of the Acessa Guidance System, we’re fulfilling our promise of advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids.”

“As a gynecologist, I’m very excited by the next generation system. I’ve been offering Acessa as a minimally invasive alternative to hysterectomy and myomectomy since it was first available through clinical trial. With the availability of the Acessa Guidance System, it’s now the first line treatment I offer patients looking for a uterine-sparing, outpatient procedure and who want to be back to work in just a few days,” said Dr. Don Galen, Medical Director, Halt Medical, Inc. “It truly is game-changing technology in the field of gynecology.”

About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Brentwood, CA.

CONTACT: Kim Bridges, President and CEO of Halt Medical, Inc., kbridges@haltmedical.com, (925) 634-7943.

¹Patented AIM™ guidance software provided by InnerOptic Technology, Inc.

LI-00-0515-A

X
- Enter Your Location -
- or -